ANGLE PLC

Regulatory Filings • Jan 14, 2013

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 4215V

Angle PLC

14 January 2013

For immediate release	14 January 2013

ANGLE plc

("ANGLE" or "the Company")

PARSORTIX CELL RECOVERY

ANGLE plc (AIM: AGL), the specialist medtech company, is delighted to announce that the Company has achieved a major new breakthrough in the potential use of its Parsortix non-invasive cancer diagnostic product. 

In addition to the technology's ability to capture and count very rare circulating tumour cells (CTCs) from the blood of cancer patients, ANGLE has developed a process for recovering captured cells from the Parsortix cassette. 

This recovery capability gives the potential for the cells captured by the Parsortix cassette to be analysed by a variety of contemporary molecular techniques.  Enabling CTC analysis using these techniques substantially extends the Parsortix technology's capability, opens up many new diagnostic, prognostic and treatment applications for cancer patients, and greatly increases the size of the market available to ANGLE.

There is no device currently in the market designed to recover CTCs and as a result there is a major unmet medical need.  Of the various systems known to be under development, a major differentiator of the Parsortix technology is that it offers the potential to recover intact, living cells. 

Analysis of CTCs can be used to screen and diagnose patients and importantly to monitor response to treatment in a non-invasive manner without having to perform a tumour biopsy.  ANGLE's research partner, the Paterson Institute for Cancer Research, is a world leader in developing medical applications in this field and it will be investigating the potential for the Parsortix system to be used as a source of CTCs for these applications. 

ANGLE's Founder and Chief Executive, Andrew Newland, commented:

"This major development means that our system now offers two approaches to analysis of CTCs: counting and identification of cells captured within the cassette; and molecular analysis of cells recovered from the cassette as a liquid biopsy.  We know from discussions with researchers and physicians that there is market demand for this versatility." 

For further information:

ANGLE plc	01483 685830
Andrew Newland, Chief Executive Ian Griffiths, Finance Director
Cenkos Securities Stephen Keys, Adrian Hargrave (Nominated adviser) Andy Roberts, Christian Hobart (Sales)	020 7397 8900
Buchanan Mark Court, Fiona Henson, Sophie Cowles	020 7466 5000

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCNKNDKDBKBDDD